Tuesday - May 19, 2026
Baxfendy Approved in the U.S. as the First and Only Aldosterone Synthase Inhibitor Treatment for Adults With Fypertension
May 19, 2026
WILMINGTON, Delaware, May 19 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Approval based on BaxHTN Phase III results showing statistically significant and

clinically meaningful reduction in systolic blood pressure in patients with

uncontrolled or resistant hypertension

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products